The Brazilian government temporarily halted the use of the dengue vaccine developed by Butantan Institute on Thursday, citing the need for further evaluation of safety and efficacy data, according to health officials. The decision follows concerns raised by regulatory bodies about the vaccine’s performance in specific population groups.
The suspension applies to the vaccine, known as Butantan’s dengue vaccine, which was approved for use in 2023 after a series of clinical trials. The move comes amid ongoing investigations into reports of adverse events and discrepancies in trial results, though no definitive link to the vaccine has been established, according to the Ministry of Health.
“The suspension is not a condemnation of the vaccine but a precautionary measure to ensure public safety,” said Dr. José Carlos de Almeida, director of the Butantan Institute. “We are committed to a rigorous review of all data to address any uncertainties.”
The vaccine was initially hailed as a breakthrough in combating dengue, a mosquito-borne disease that affects millions across Brazil annually. However, recent analyses of real-world usage data have highlighted variations in effectiveness, particularly among individuals with prior dengue exposure. Public health authorities emphasized that the suspension does not affect the broader dengue control strategy, which includes vector reduction and other preventive measures.
Health officials stated that the review process will involve independent experts and could take several weeks. The Ministry of Health reiterated that the vaccine remains available for use in controlled settings while the investigation continues. No new cases of severe adverse effects have been reported since the suspension, though monitoring efforts are ongoing.
The decision has sparked debate among medical professionals. Some argue that the pause could delay critical immunization efforts in high-risk regions, while others support the cautious approach to ensure long-term public trust. “Transparency is essential,” said Dr. Maria Helena Guimarães, a public health researcher. “The data must be scrutinized to avoid potential risks.”
What’s next? The Butantan Institute and regulatory agencies plan to release a detailed report on the vaccine’s performance by the end of the month. In the interim, health providers are advised to follow updated guidelines for dengue prevention and to consult with specialists before administering the vaccine to high-risk patients.
